Shire could 'tolerate' one more acquisition, CEO says

Outsourcing development has allowed Shire to grow to $2.9 billion in revenues with only 5,000 employees worldwide, CEO Angus Russell tells This is Money. Report

Suggested Articles

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.